Bank of New York Mellon’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-94,895
| Closed | -$1.4M | – | 4341 |
|
|
2024
Q1 | $1.4M | Sell |
94,895
-5,302
| -5% | -$74.5K | ﹤0.01% | 2966 |
|
|
2023
Q4 | $1.34M | Buy |
100,197
+494
| +0.5% | +$6.24K | ﹤0.01% | 3033 |
|
|
2023
Q3 | $1.23M | Sell |
99,703
-614
| -0.6% | -$7.43K | ﹤0.01% | 3049 |
|
|
2023
Q2 | $1.23M | Buy |
100,317
+25,437
| +34% | +$318K | ﹤0.01% | 3084 |
|
|
2023
Q1 | $920K | Hold |
74,880
| – | – | ﹤0.01% | 3170 |
|
|
2022
Q4 | $858K | Buy |
74,880
+33,929
| +83% | +$279K | ﹤0.01% | 3267 |
|
|
2022
Q3 | $153K | Hold |
40,951
| – | – | ﹤0.01% | 4113 |
|
|
2022
Q2 | $244K | Sell |
40,951
-45
| -0.1% | -$254 | ﹤0.01% | 3981 |
|
|
2022
Q1 | $259K | Hold |
40,996
| – | – | ﹤0.01% | 4100 |
|
|
2021
Q4 | $160K | Hold |
40,996
| – | – | ﹤0.01% | 4338 |
|
|
2021
Q3 | $198K | Hold |
40,996
| – | – | ﹤0.01% | 4220 |
|
|
2021
Q2 | $262K | Sell |
40,996
-1,229
| -3% | -$8.11K | ﹤0.01% | 4006 |
|
|
2021
Q1 | $265K | Buy |
42,225
+24,682
| +141% | +$176K | ﹤0.01% | 3961 |
|
|
2020
Q4 | $121K | Buy |
17,543
+31
| +0.2% | +$153 | ﹤0.01% | 4055 |
|
|
2020
Q3 | $70K | Hold |
17,512
| – | – | ﹤0.01% | 3987 |
|
|
2020
Q2 | $58K | Buy |
17,512
+1
| +0% | +$3 | ﹤0.01% | 3967 |
|
|
2020
Q1 | $38K | Sell |
17,511
-120
| -0.7% | -$351 | ﹤0.01% | 4003 |
|
|
2019
Q4 | $56K | Hold |
17,631
| – | – | ﹤0.01% | 4097 |
|
|
2019
Q3 | $79K | Sell |
17,631
-4,778
| -21% | -$23.9K | ﹤0.01% | 4061 |
|
|
2019
Q2 | $107K | Hold |
22,409
| – | – | ﹤0.01% | 4021 |
|
|
2019
Q1 | $123K | Sell |
22,409
-793
| -3% | -$3.65K | ﹤0.01% | 3972 |
|
|
2018
Q4 | $70K | Buy |
+23,202
| New | +$80.5K | ﹤0.01% | 4016 |
|
|
2018
Q3 | – | Sell |
-54,741
| Closed | -$211K | – | 4316 |
|
|
2018
Q2 | $211K | Sell |
54,741
-46,209
| -46% | -$307K | ﹤0.01% | 3914 |
|
|
2018
Q1 | $639K | Sell |
100,950
-997
| -1% | -$8.25K | ﹤0.01% | 3459 |
|
|
2017
Q4 | $822K | Buy |
101,947
+14,184
| +16% | +$132K | ﹤0.01% | 3360 |
|
|
2017
Q3 | $1M | Sell |
87,763
-2,033
| -2% | -$21.4K | ﹤0.01% | 3229 |
|
|
2017
Q2 | $876K | Sell |
89,796
-2,759
| -3% | -$56.4K | ﹤0.01% | 3322 |
|
|
2017
Q1 | $2.24M | Buy |
92,555
+1,736
| +2% | +$43.4K | ﹤0.01% | 2786 |
|
|
2016
Q4 | $2.92M | Buy |
90,819
+7,160
| +9% | +$305K | ﹤0.01% | 2627 |
|
|
2016
Q3 | $4.18M | Sell |
83,659
-2,518
| -3% | -$105K | ﹤0.01% | 2331 |
|
|
2016
Q2 | $3.65M | Buy |
86,177
+2,270
| +3% | +$124K | ﹤0.01% | 2375 |
|
|
2016
Q1 | $5.53M | Buy |
83,907
+1,103
| +1% | +$57.6K | ﹤0.01% | 2120 |
|
|
2015
Q4 | $5.15M | Buy |
82,804
+1,203
| +1% | +$84.6K | ﹤0.01% | 2199 |
|
|
2015
Q3 | $5.46M | Sell |
81,601
-21,299
| -21% | -$1.74M | ﹤0.01% | 2184 |
|
|
2015
Q2 | $10M | Buy |
102,900
+6,024
| +6% | +$573K | ﹤0.01% | 1965 |
|
|
2015
Q1 | $9.06M | Sell |
96,876
-260
| -0.3% | -$22.1K | ﹤0.01% | 2000 |
|
|
2014
Q4 | $8.64M | Sell |
97,136
-1,207
| -1% | -$87.9K | ﹤0.01% | 1999 |
|
|
2014
Q3 | $6.79M | Sell |
98,343
-3,093
| -3% | -$165K | ﹤0.01% | 2123 |
|
|
2014
Q2 | $5.82M | Sell |
101,436
-32,228
| -24% | -$1.64M | ﹤0.01% | 2242 |
|
|
2014
Q1 | $5.3M | Buy |
133,664
+2,193
| +2% | +$93.8K | ﹤0.01% | 2288 |
|
|
2013
Q4 | $5.51M | Buy |
131,471
+2,479
| +2% | +$71.9K | ﹤0.01% | 2237 |
|
|
2013
Q3 | $3.85M | Sell |
128,992
-3,322
| -3% | -$116K | ﹤0.01% | 2398 |
|
|
2013
Q2 | $7.02M | Buy |
+132,314
| New | +$5.8M | ﹤0.01% | 1993 |
|
Other funds holding MACK
RA
JC
Bank of New York Mellon's MACK Position: Q2 2024 in Review
Bank of New York Mellon sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 94,895 shares — an estimated $1.4M sold.
Bank of New York Mellon first reported a position in MACK in Q2 2013 and held it in 43 quarters. The position peaked at $10M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Bank of New York Mellon reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 94,895 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1.4M.
- Bank of New York Mellon first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 43 quarters.
- Bank of New York Mellon's Merrimack Pharmaceuticals, Inc. position peaked at $10M in Q2 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.